Whitepapers


All series


All Whitepapers

Supply chain woes existed long before the pandemic, and not many scientists want to spend time sourcing ingredients. There is a way to ensure you get the right active pharmaceutical ingredients, at the right cost, with the right plan to scale: partnering with an API procurement and supply chain specialist. Download our white paper to learn five reasons to outsource API procurement.

What if you could rely on one partner to source APIs, formulate and develop drug products, and manufacture at clinical and commercial scale? Rather than too many links in your supply chain, an end-to-end CDMO reduces layers of administration, gaps in knowledge, time, cost, and risk. Download our white paper to learn the five “must ask” questions to find the right CDMO.

When the patent on a brand-name dental paste expired, our client saw an opportunity to offer sufferers of painful oral lesions a generic alternative. Their product would drive down costs for patients while positioning the client’s business for success in a competitive market. With the FDA’s Abbreviated New Drug Application (ANDA) regulatory pathway leading the way forward, all they needed was a partner with experience developing and manufacturing unique semi-solid products. That’s when they found LGM Pharma. Read our case study.

Large volume parenteral applications are characterized by high volume doses of a drug product, which are administered intravenously. Flexible bag systems, which contain a combination of different materials, are often used as container/closure systems. Definitions and regulatory requirements for extractables and leachables testing of large volume parenteral products, will be highlighted. Next, typical sources of extractables and leachables in flexible bag systems for parenteral use will be listed. Emphasis will be put on the specific challenges associated with large volume parenteral applications. Finally, some case studies regarding different designs of extractable studies will be discussed.

Meet the soloPURE™ flexible aseptic isolator, a cost-effective closed-barrier system for sterile manufacturing that provides a closed Grade-A, aseptic environment for fill finish activities requiring positive and negative pressures.

When selecting and qualifying the primary packaging for lyophilized drug products (LDPs), one of the obvious questions is How far should one go into the E&L-qualification process? As the drug product is in a solid state, one would expect that the interaction between the LDP and the components of its container would be low. But is this really the case? Watch this webinar to learn more.

The function of a pharmaceutical drug product or a medical device is to provide the patient with a desired therapeutic benefit. If the drug product or the medical device were pure (meaning without impurities), ideally the therapeutic benefit would be largely realized with minimal adverse patient effects. However, since the practical reality is that drug products and medical devices contain impurities, a patient is exposed to these impurities during treatment and these impurities could potentially trigger an increase of adverse patient effects.